Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a Three-Pronged attack keep High-Risk leukemia at bay?

NCT ID NCT06158100

Terminated Disease control Sponsor: Antonio M Jimenez Jimenez Source: ClinicalTrials.gov ↗

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This phase 1 trial is testing whether a combination of two drugs (venetoclax and azacitidine) followed by donor immune cell infusions can prevent relapse in people with very high-risk acute myeloid leukemia (AML) who have already received a stem cell transplant. The study enrolls adults aged 18 to 75 whose AML is in remission but who still have a high chance of the cancer coming back. The main goals are to find the safest dose and to see if the treatment is well tolerated.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
venetoclax, azacitidine, and donor lymphocyte infusion
What this could lead to
If successful, this combination could help prevent AML from returning after a stem cell transplant, potentially improving long-term survival for very high-risk patients.
What could go wrong
This is a very early phase 1 study with only a small number of participants, so safety and effectiveness are not yet established. The combination may cause significant side effects, and it is unknown whether it will actually reduce relapse rates.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA

Contacts and locations

Locations

  • University of Miami

    Miami, Florida, 33136, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.